Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
$9.50
-2.9%
$11.16
$9.22
$14.63
$1.14B1.262.21 million shs2.31 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$6.92
-6.2%
$6.58
$5.01
$23.86
$1.12B3.217.20 million shs7.89 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.30
-0.8%
$1.43
$1.19
$2.04
$1.03B1.423.89 million shs1.77 million shs
XOMA Co. stock logo
XOMA
XOMA
$25.15
+0.9%
$22.76
$18.35
$35.00
$300.97M0.8930,878 shs20,449 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
-2.86%-4.04%-15.71%-30.04%-17.39%
Novavax, Inc. stock logo
NVAX
Novavax
-6.23%-2.67%+3.28%-1.98%-55.40%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-0.76%0.00%-7.80%-20.25%-4.41%
XOMA Co. stock logo
XOMA
XOMA
+0.92%+0.12%+2.19%+10.79%-1.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
4.4617 of 5 stars
3.33.00.04.72.71.71.9
Novavax, Inc. stock logo
NVAX
Novavax
3.5587 of 5 stars
3.21.00.04.72.70.80.6
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.3922 of 5 stars
3.42.00.04.42.45.00.6
XOMA Co. stock logo
XOMA
XOMA
4.397 of 5 stars
3.54.00.03.03.13.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
2.50
Moderate Buy$24.00152.63% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.43
Hold$19.00174.57% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.75
Moderate Buy$2.75111.54% Upside
XOMA Co. stock logo
XOMA
XOMA
3.00
Buy$69.50176.34% Upside

Current Analyst Ratings Breakdown

Latest XOMA, DVAX, NVAX, and OPK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
XOMA Co. stock logo
XOMA
XOMA
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00
5/19/2025
Novavax, Inc. stock logo
NVAX
Novavax
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/9/2025
Novavax, Inc. stock logo
NVAX
Novavax
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.00
5/7/2025
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $31.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
4/17/2025
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$12.00 ➝ $10.00
4/17/2025
XOMA Co. stock logo
XOMA
XOMA
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$35.00
4/7/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
3/28/2025
XOMA Co. stock logo
XOMA
XOMA
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$104.00 ➝ $104.00
3/19/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
$294.62M3.87N/AN/A$4.81 per share1.98
Novavax, Inc. stock logo
NVAX
Novavax
$1.21B0.92N/AN/A($6.04) per share-1.15
OPKO Health, Inc. stock logo
OPK
OPKO Health
$689.41M1.50N/AN/A$1.80 per share0.72
XOMA Co. stock logo
XOMA
XOMA
$13.05M23.07N/AN/A$7.72 per share3.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
-$6.39M-$0.5252.7819.39N/A9.85%4.22%2.67%8/5/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$545.06M$2.65N/A86.502.85-32.18%N/A-17.05%8/14/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$188.86M-$0.07N/AN/AN/A-18.65%-9.76%-6.46%8/6/2025 (Estimated)
XOMA Co. stock logo
XOMA
XOMA
-$40.83M-$1.15N/AN/AN/A-151.34%-24.95%-9.64%8/12/2025 (Estimated)

Latest XOMA, DVAX, NVAX, and OPK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
XOMA Co. stock logo
XOMA
XOMA
-$0.26$0.06+$0.32$0.06$6.75 million$15.91 million
5/8/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.71$2.93+$2.22$2.93$204.08 million$666.66 million
5/6/2025Q1 2025
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 million
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
3/17/2025Q4 2024
XOMA Co. stock logo
XOMA
XOMA
-$0.29-$0.46-$0.17-$0.46$8.75 million$8.70 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
XOMA Co. stock logo
XOMA
XOMA
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
0.33
13.23
12.34
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.93
0.93
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.30
2.97
2.69
XOMA Co. stock logo
XOMA
XOMA
1.28
7.52
7.52

Institutional Ownership

CompanyInstitutional Ownership
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
96.96%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
XOMA Co. stock logo
XOMA
XOMA
95.92%

Insider Ownership

CompanyInsider Ownership
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
2.98%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
XOMA Co. stock logo
XOMA
XOMA
9.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dynavax Technologies Co. stock logo
DVAX
Dynavax Technologies
350120.08 million127.54 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990161.97 million158.58 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
4,200793.05 million359.94 millionOptionable
XOMA Co. stock logo
XOMA
XOMA
1011.97 million10.94 millionOptionable

Recent News About These Companies

XOMA boosts stake in anti-CD38 antibody with $30 million deal
XOMA Royalty Reports Strong Q1 2025 Results
XOMA Royalty: Q1 Earnings Snapshot
High Growth Tech Stocks In The US To Watch April 2025
Xoma initiated with a Buy at Benchmark

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dynavax Technologies stock logo

Dynavax Technologies NASDAQ:DVAX

$9.50 -0.28 (-2.86%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$9.62 +0.12 (+1.22%)
As of 06:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Novavax stock logo

Novavax NASDAQ:NVAX

$6.92 -0.46 (-6.23%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$7.14 +0.22 (+3.11%)
As of 06:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.30 -0.01 (-0.76%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$1.33 +0.03 (+2.31%)
As of 06:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

XOMA stock logo

XOMA NASDAQ:XOMA

$25.15 +0.23 (+0.92%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$25.17 +0.02 (+0.08%)
As of 05/28/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.